Informace o publikaci

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021

Autoři	ANGELA MC Rose NICOLAY Nathalie MARTIN Virginia Sandonis MAZAGATOS Clara PETROVIC Goranka NIESSEN F Annabel MACHADO Ausenda LAUNAY Odile DENAYER Sarah SEYLER Lucie BARUCH Joaquin BURGUI Cristina LOGHIN Isabela I DOMEGAN Lisa VAIKUTYTE Roberta HUSA Petr PANAGIOTAKOPOULOS George AOUALI Nassera DUERRWALD Ralf HOWARD Jennifer POZO Francisco SASTRE-PALOU Bartolome NONKOVIC Diana KNOL Mirjam J KISLAYA Irina NGUYEN Liem Binh Luong BOSSUYT Nathalie DEMUYSER Thomas DZIUGYTE Ausra MARTINEZ-BAZ Ivan POPESCU Corneliu DUFFY Roisin KULIESE Monika SOUČKOVÁ Lenka MICHELAKI Stella SIMON Marc REICHE Janine OTERO-BARROS Maria Teresa MAKARIC Zvjezdana Lovric BRUIJNING-VERHAGEN Patricia C J L GOMEZ Veronica LESIEUR Zineb BARBEZANGE Cyril ELS Van Nedervelde BORG Maria-Louise CASTILLA Jesus LAZAR Mihaela DONNELL Joan JONIKAITE Indre DEMLOVÁ Regina AMERALI Marina WIRTZ Gil TOLKSDORF Kristin VALENCIANO Marta BACCI Sabrina KISSLING Esther
Rok publikování	2023
Druh	Článek v odborném periodiku
Časopis / Zdroj	EUROSURVEILLANCE
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.47.2300186
Doi	http://dx.doi.org/10.2807/1560-7917.ES.2023.28.47.2300186
Klíčová slova	Alpha; Delta; Europe; hospital; SARS-CoV-2; vaccine effectiveness
Popis	IntroductionTwo large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients >= 20 years, combining data from these networks during Alpha (March-June)- and Delta (June-December)-dominant periods, 2021.MethodsForty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case-control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine >= 14 days before onset.ResultsWe included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69-92) overall and 75% (95% CI: 42-90) in those aged >= 80 years. During the Delta period, among SARI patients >= 20 years with symptom onset >= 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18-74). Among those receiving Comirnaty PSV and mRNA booster (any product) >= 150 days after last PSV dose, VE was 91% (95% CI: 57-98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose < 90 days before onset; >= 70% in those 90-179 days before onset.ConclusionsOur results from this EU multi-country hospital setting showed that VE for complete PSV alone was higher in the Alpha- than the Delta-dominant period, and addition of a first booster dose during the latter period increased VE to over 90%.